RAMM Pharma Stock Price

CNSX:RAMMCA$1.2mPharmaceuticals & Biotech

RAMM Share Price Performance

RAMM Community Fair Values

RenovoRx
ST
Stock_Research_Today
Community Contributor
Revolutionizing Cancer Treatment
A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.
View narrative
US$4.20
FV
66.9% undervalued intrinsic discount
371.30%
Revenue growth p.a.
11users have liked this narrative
3users have commented on this narrative
108users have followed this narrative
about 1 month ago author updated this narrative
Your Fair Value
CA$
Current Price
CA$0.0187.7% undervalued intrinsic discount
Growth estimate over
Annual revenue growth rate
%/yr
Decrease
Increase
Advanced

View all narratives

Recent RAMM News & Updates

RAMM Pharma Corp. Competitors

View more competitors

RAMM Pharma Corp. Key Details

Last Reported Earnings

Jan 31, 2025

Yearly revenue growth

n/a

Earnings per share (EPS): -0.13
Gross Margin: 39.79%
Net Profit Margin: -346.45%
Debt/Equity Ratio: 0%

View full report ›

Canadian Market Performance

7 Days: 0.4%
3 Months: 7.8%
1 Year: 15.7%
Year to Date: 6.1%

The Materials sector gained 4.1% while the market remained flat over the last week. Meanwhile, the market is actually up 16% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

🤖 A.I. Enters the “Show Me The Money” Phase

Richard Bowman

May 2025

The AI frenzy of 2023 and 2024 has cooled down and entered the "show me the money" phase. Earnings season has shed a lot of light on where we stand. So it’s time for an update on the industry and a look at the companies successfully deploying AI, monetizing it, and the potential opportunities for investors.

Last Week

RAMM Pharma Stock Price

RAMM Share Price Performance

RAMM Community Fair Values

Revolutionizing Cancer Treatment

Recent RAMM News & Updates

Insufficient new directors

First quarter 2025 earnings released: CA$0.009 loss per share (vs CA$0.019 loss in 1Q 2024)

Insufficient new directors

RAMM Pharma Corp. Provides Update on Litigation

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.01 loss in 2Q 2023)

RAMM Pharma Corp., Annual General Meeting, Aug 09, 2024

New major risk - Financial position

RAMM Pharma Corp. Competitors

🤖 A.I. Enters the “Show Me The Money” Phase

🧬 The Convergence of Genomic Medicine and AI Drug Discovery